Renagade Therapeutics
Latest round
- Series A
Last raised
- May 2023
Total raised
- $300M
Investors
- 2
About Renagade Therapeutics
Founded in 2021 and based in Massachusetts, US, Renagade Therapeutics, Inc. operates as a biotechnology platform that provides RNA medicines and research to cure diseases. As of 2023, Amit Munshi serves as the CEO of the company. In May 2023, Renagade Therapeutics, Inc. The company has developed a portfolio of RNA delivery methods, broadening the variety of disorders that can be addressed. The firm can deliver RNA, reprogram cells with increased expression, and partner with Orna Therapeutics to harness the RNA coding platform using its synergistic toolkit. Renagade offers expertise that includes a wide range of delivery technologies as well as a synergistic RNA toolbox that enables transport, coding, editing, and insertion. The company's technological capability allows it to possibly treat any disease, everywhere in the body, with RNA therapeutics.
Who invested in Renagade Therapeutics
2 investors across 1 round
See all investors in Renagade Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
May 23, 2023
Amount
$300M
Investors
Questions about Renagade Therapeutics
Who invested in Renagade Therapeutics?
Renagade Therapeutics has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Renagade Therapeutics raised?
Renagade Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Renagade Therapeutics last raise money?
Renagade Therapeutics's most recent round on record is a Series A, in May 2023.
What does Renagade Therapeutics do?
Founded in 2021 and based in Massachusetts, US, Renagade Therapeutics, Inc.
Where is Renagade Therapeutics headquartered?
Renagade Therapeutics is headquartered in Cambridge, US.
Which VCs invest in companies like Renagade Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Renagade Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Renagade Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.